Blau Farmacêutica S.A. (BVMF:BLAU3)
9.62
-0.18 (-1.84%)
At close: Mar 20, 2026
Blau Farmacêutica Balance Sheet
Financials in millions BRL. Fiscal year is January - December.
Millions BRL. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 45.6 | 33.32 | 31.5 | 14.11 | 51.86 |
Short-Term Investments | 569.49 | 459.56 | 375.82 | 629.53 | 870.96 |
Cash & Short-Term Investments | 615.09 | 492.87 | 407.31 | 643.65 | 922.82 |
Cash Growth | 24.80% | 21.00% | -36.72% | -30.25% | 330.52% |
Accounts Receivable | 458.47 | 476.75 | 453.56 | 420.61 | 331.79 |
Other Receivables | 129.54 | 100.34 | 64.35 | 44.58 | 13.66 |
Receivables | 588.02 | 577.09 | 517.91 | 465.19 | 345.45 |
Inventory | 694.13 | 606.19 | 628.65 | 569.02 | 416.85 |
Other Current Assets | - | - | - | - | 11.35 |
Total Current Assets | 1,897 | 1,676 | 1,554 | 1,678 | 1,696 |
Property, Plant & Equipment | 1,011 | 829.04 | 738.71 | 542.48 | 371.58 |
Long-Term Investments | - | 265.16 | 265.19 | - | 0.04 |
Goodwill | - | 151.66 | 151.66 | 143.24 | 143.24 |
Other Intangible Assets | 617.11 | 53.81 | 24.83 | 16.57 | 5.75 |
Long-Term Deferred Tax Assets | 77.8 | 84.52 | 81.53 | - | - |
Long-Term Deferred Charges | - | 282.28 | 177.58 | 74.25 | 49.82 |
Other Long-Term Assets | 31.92 | 69.12 | 60.17 | 44.65 | 61.14 |
Total Assets | 3,635 | 3,412 | 3,054 | 2,499 | 2,328 |
Accounts Payable | 266.38 | 286 | 179.92 | 163.64 | 116.43 |
Accrued Expenses | 89.21 | 90.21 | 55.62 | 56.78 | 55.2 |
Short-Term Debt | 94.49 | 1.87 | 2.3 | - | 41.73 |
Current Portion of Long-Term Debt | 184.03 | 65.1 | 67.92 | 79.87 | 49.82 |
Current Portion of Leases | 7.07 | 6.39 | 4.8 | 3.67 | 2.11 |
Current Income Taxes Payable | 0.03 | 8.92 | - | 19.44 | 19.99 |
Other Current Liabilities | 127.24 | 79.46 | 25.38 | 47.71 | 57.72 |
Total Current Liabilities | 768.45 | 537.94 | 335.93 | 371.11 | 343.01 |
Long-Term Debt | 283.33 | 450 | 500 | 200 | 272.5 |
Long-Term Leases | 30.21 | 35.59 | 33.52 | 28.17 | 8.35 |
Long-Term Deferred Tax Liabilities | 221.98 | 170.2 | 125.64 | 35.02 | 18.25 |
Other Long-Term Liabilities | 75.32 | 67.33 | 63.2 | 46.81 | 51.05 |
Total Liabilities | 1,379 | 1,261 | 1,058 | 681.11 | 693.16 |
Common Stock | 1,717 | 1,317 | 1,317 | 1,317 | 1,317 |
Retained Earnings | 612.28 | 899.32 | 744.37 | 562.8 | 325.13 |
Treasury Stock | -42.89 | -42.89 | -42.89 | -39.9 | - |
Comprehensive Income & Other | -14.23 | -9.05 | -16.62 | -17.36 | -5.45 |
Total Common Equity | 2,272 | 2,164 | 2,001 | 1,822 | 1,636 |
Minority Interest | -16.02 | -13.33 | -6.22 | -4.22 | -1.4 |
Shareholders' Equity | 2,256 | 2,151 | 1,995 | 1,818 | 1,635 |
Total Liabilities & Equity | 3,635 | 3,412 | 3,054 | 2,499 | 2,328 |
Total Debt | 599.13 | 558.95 | 608.54 | 311.71 | 374.52 |
Net Cash (Debt) | 15.95 | -66.08 | -201.22 | 331.93 | 548.3 |
Net Cash Growth | - | - | - | -39.46% | - |
Net Cash Per Share | - | -0.29 | -0.87 | 1.44 | 2.35 |
Filing Date Shares Outstanding | - | 230.98 | 230.98 | 231.18 | 233.21 |
Total Common Shares Outstanding | - | 230.98 | 230.98 | 231.18 | 233.21 |
Working Capital | 1,129 | 1,138 | 1,218 | 1,307 | 1,353 |
Book Value Per Share | - | 9.37 | 8.66 | 7.88 | 7.02 |
Tangible Book Value | 1,655 | 1,959 | 1,825 | 1,662 | 1,487 |
Tangible Book Value Per Share | - | 8.48 | 7.90 | 7.19 | 6.38 |
Machinery | - | 338.57 | 302.14 | 170.92 | 135.22 |
Construction In Progress | - | 296.26 | 257.03 | 210.19 | 194.06 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.